At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Hypofractionated Radiation Therapy After Mastectomy in Patients With Stage IIa-IIIa Breast Cancer

Clinical Trial Title: 
Hypofractionated radiation therapy after mastectomy in preventing recurrence in patients with stage IIa-IIIa breast cancer.
Clinical Trial Protocol ID: 
18073001
Clinical Trial Investigator Name: 
Parul Barry, MD
Clinical Trial Protocol Description: 

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have histologically confirmed invasive carcinoma of the breast of any of the following histologies: ductal, lobular, mammary, medullary, or tubular.
  • Have had no prior therapeutic radiation therapy to the chest, neck or axilla. Prior radioactive oral iodine is permitted.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

You will be excluded from the study if any of the following criteria apply to you:

  • Have clinical or radiological evidence of metastatic disease.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Breast Cancer
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office